Indian pharma can’t afford to miss governance bus amid growth focus
ET Intelligence Group: The emergence of India as a key growth driver for pharma companies is coinciding with an increase in regulatory scrutiny at home.
Inadequate Disclosures Related to USFDA Audits: Two weeks ago, capital-markets…